Zolgensma-话题@MedSci - williamhill asia

#Zolgensma#

9篇内容 | 907人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1640559, encodeId=1f4a1640559dc, content=<a href='/topic/show?id=af9d19083bc' target=_blank style='color:#2F92EE;'>#Zolgensma#</a>, objectTitle=两名儿童接受最贵的基因治疗药物Zolgensma治疗后死于肝功能衰竭，正在调查原因, objectType=article, longId=735707, objectId=5082e35707b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5082e35707b6, replyNumber=0, likeNumber=55, createdTime=2023-02-07, rootId=0, userName=12498a1cm74暂无昵称, userId=bf0722658792, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5082e35707b6, moduleTitle=两名儿童接受最贵的基因治疗药物Zolgensma治疗后死于肝功能衰竭，正在调查原因, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5082e35707b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1640558, encodeId=0a3e1640558ca, content=<a href='/topic/show?id=af9d19083bc' target=_blank style='color:#2F92EE;'>#Zolgensma#</a>, objectTitle=1348万Zolgensma，一针治愈遗传病脊髓性肌萎缩症（SMA）, objectType=article, longId=294923, objectId=f98b294923a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f98b294923a6, replyNumber=0, likeNumber=55, createdTime=2022-03-30, rootId=0, userName=12498a1cm74暂无昵称, userId=bf0722658792, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f98b294923a6, moduleTitle=1348万Zolgensma，一针治愈遗传病脊髓性肌萎缩症（SMA）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f98b294923a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1640557, encodeId=5b4c164055ec9, content=<a href='/topic/show?id=af9d19083bc' target=_blank style='color:#2F92EE;'>#Zolgensma#</a>, objectTitle=JAMA Neurol：Zolgensma治疗后5年，脊髓性肌肉萎缩症患者仍可获得长期临床缓解, objectType=article, longId=211985, objectId=93e021198556, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93e021198556, replyNumber=0, likeNumber=87, createdTime=2021-11-27, rootId=0, userName=12498a1cm74暂无昵称, userId=bf0722658792, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93e021198556, moduleTitle=JAMA Neurol：Zolgensma治疗后5年，脊髓性肌肉萎缩症患者仍可获得长期临床缓解, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=93e021198556)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1640555, encodeId=e43d1640555a6, content=<a href='/topic/show?id=af9d19083bc' target=_blank style='color:#2F92EE;'>#Zolgensma#</a>, objectTitle=5年随访数据证明Zolgensma基因疗法针对脊髓性肌萎缩症的安全性和有效性, objectType=article, longId=190825, objectId=4f7c19082592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f7c19082592, replyNumber=0, likeNumber=67, createdTime=2020-05-05, rootId=0, userName=12498a1cm74暂无昵称, userId=bf0722658792, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f7c19082592, moduleTitle=5年随访数据证明Zolgensma基因疗法针对脊髓性肌萎缩症的安全性和有效性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=4f7c19082592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1640556, encodeId=0dd916405568b, content=<a href='/topic/show?id=af9d19083bc' target=_blank style='color:#2F92EE;'>#Zolgensma#</a>, objectTitle=诺华的天价基因疗法Zolgensma，在欧洲获批治疗脊柱性肌肉萎缩症, objectType=article, longId=194459, objectId=50e81944593f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50e81944593f, replyNumber=0, likeNumber=48, createdTime=2020-06-18, rootId=0, userName=12498a1cm74暂无昵称, userId=bf0722658792, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50e81944593f, moduleTitle=诺华的天价基因疗法Zolgensma，在欧洲获批治疗脊柱性肌肉萎缩症, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=50e81944593f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1640554, encodeId=d8ca1640554f5, content=<a href='/topic/show?id=af9d19083bc' target=_blank style='color:#2F92EE;'>#Zolgensma#</a>, objectTitle=诺华的基因疗法Zolgensma，在日本获批治疗脊髓性肌萎缩症（SMA）儿童患者, objectType=article, longId=190503, objectId=eb4819050376, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb4819050376, replyNumber=0, likeNumber=59, createdTime=2020-12-23, rootId=0, userName=12498a1cm74暂无昵称, userId=bf0722658792, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb4819050376, moduleTitle=诺华的基因疗法Zolgensma，在日本获批治疗脊髓性肌萎缩症（SMA）儿童患者, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=eb4819050376)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1640553, encodeId=ebb1164055391, content=<a href='/topic/show?id=af9d19083bc' target=_blank style='color:#2F92EE;'>#Zolgensma#</a>, objectTitle=FDA暂时搁置了对鞘内施用SMA基因疗法Zolgensma的研究, objectType=article, longId=182191, objectId=2b0518219190, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b0518219190, replyNumber=0, likeNumber=75, createdTime=2020-06-17, rootId=0, userName=12498a1cm74暂无昵称, userId=bf0722658792, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b0518219190, moduleTitle=FDA暂时搁置了对鞘内施用SMA基因疗法Zolgensma的研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=2b0518219190)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1640552, encodeId=880216405529f, content=<a href='/topic/show?id=af9d19083bc' target=_blank style='color:#2F92EE;'>#Zolgensma#</a>, objectTitle=诺华的脊髓性肌萎缩症基因治疗药物Zolgensma，临床试验中出现第二次死亡事件, objectType=article, longId=164833, objectId=2160164833a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2160164833a3, replyNumber=0, likeNumber=68, createdTime=2020-01-08, rootId=0, userName=12498a1cm74暂无昵称, userId=bf0722658792, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2160164833a3, moduleTitle=诺华的脊髓性肌萎缩症基因治疗药物Zolgensma，临床试验中出现第二次死亡事件, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=2160164833a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1640551, encodeId=d518164055153, content=<a href='/topic/show?id=af9d19083bc' target=_blank style='color:#2F92EE;'>#Zolgensma#</a>, objectTitle=III期临床结果证实AveXis的基因疗法Zolgensma对I型脊髓性肌萎缩症的有效性, objectType=article, longId=164499, objectId=73ff16449919, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73ff16449919, replyNumber=0, likeNumber=58, createdTime=2019-08-31, rootId=0, userName=12498a1cm74暂无昵称, userId=bf0722658792, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73ff16449919, moduleTitle=III期临床结果证实AveXis的基因疗法Zolgensma对I型脊髓性肌萎缩症的有效性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=73ff16449919)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

Zolgensma

2020-05-29

12498a1cm74暂无昵称 (审核中...)

前往app查看评论内容

#Zolgensma#

两名儿童接受最贵的基因治疗药物Zolgensma治疗后死于肝功能衰竭，正在调查原因

2023-02-07

12498a1cm74暂无昵称 (审核中...)

前往app查看评论内容

#Zolgensma#

1348万Zolgensma，一针治愈遗传病脊髓性肌萎缩症（SMA）

2022-03-30

12498a1cm74暂无昵称 (审核中...)

前往app查看评论内容

#Zolgensma#

JAMA Neurol：Zolgensma治疗后5年，脊髓性肌肉萎缩症患者仍可获得长期临床缓解

2021-11-27

12498a1cm74暂无昵称 (审核中...)

前往app查看评论内容

#Zolgensma#

5年随访数据证明Zolgensma基因疗法针对脊髓性肌萎缩症的安全性和有效性

2020-05-05

12498a1cm74暂无昵称 (审核中...)

前往app查看评论内容

#Zolgensma#

诺华的天价基因疗法Zolgensma，在欧洲获批治疗脊柱性肌肉萎缩症

2020-06-18

12498a1cm74暂无昵称 (审核中...)

前往app查看评论内容

#Zolgensma#

诺华的基因疗法Zolgensma，在日本获批治疗脊髓性肌萎缩症（SMA）儿童患者

2020-12-23

12498a1cm74暂无昵称 (审核中...)

前往app查看评论内容

#Zolgensma#

FDA暂时搁置了对鞘内施用SMA基因疗法Zolgensma的研究

2020-06-17

12498a1cm74暂无昵称 (审核中...)

前往app查看评论内容

#Zolgensma#

诺华的脊髓性肌萎缩症基因治疗药物Zolgensma，临床试验中出现第二次死亡事件

2020-01-08

12498a1cm74暂无昵称 (审核中...)

前往app查看评论内容

#Zolgensma#

III期临床结果证实AveXis的基因疗法Zolgensma对I型脊髓性肌萎缩症的有效性

2019-08-31

科室
- - 订阅+
  - 更多科室
工具
服务